Cargando…
Longitudinal Comparison of Neutralizing Antibody Responses to COVID-19 mRNA Vaccines after Second and Third Doses
COVID-19 mRNA vaccines protect against severe disease and hospitalization. Neutralizing antibodies (NAbs) are a first-line defense mechanism, but protective NAb responses are variable. Currently, NAb testing is not widely available. This study employed a lateral flow assay for monitoring NAb levels...
Autores principales: | Roeder, Alexa J., Koehler, Megan A., Jasbi, Paniz, McKechnie, Davis, Vanderhoof, John, Edwards, Baylee A., Gonzalez-Moa, Maria J., Seit-Nebi, Alim, Svarovsky, Sergei A., Lake, Douglas F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504054/ https://www.ncbi.nlm.nih.gov/pubmed/36146537 http://dx.doi.org/10.3390/vaccines10091459 |
Ejemplares similares
-
Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
por: Lake, Douglas F., et al.
Publicado: (2022) -
Letter to the editor RE: Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’
por: Lake, Douglas F., et al.
Publicado: (2022) -
Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2
por: Lake, Douglas F., et al.
Publicado: (2021) -
Invariant amino acids essential for decoding function of polypeptide release factor eRF1
por: Kolosov, Petr, et al.
Publicado: (2005) -
General theory of light propagation and imaging through the atmosphere
por: McKechnie, T Stewart
Publicado: (2016)